Fabry Disease - Epidemiology and Market Forecast-2028

Albany, NY -- (SBWire) -- 04/17/2019 --Fabry disease - Epidemiology and Market Forecast-2028

The United States accounts for the highest number of prevalent cases of Fabry Disease with approximately 7,785 cases in 2017

1. Fabry disease prevalence is 0.3 per 100,000 in the UK
2. Fabry Disease total prevalent population in the 7 major markets is 16,688 in 2017
3. Fabry Disease patients are more likely to be females as compared to males.

DelveInsight launched a new report on Fabry disease - Market Insights, Epidemiology and Market Forecast-2028

Key benefits
1. Fabry disease epidemiology and Fabry disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Fabry disease market report provides insights on the current and emerging therapies.
3. Fabry disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Fabry disease market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Fabry disease market.

Request for sample pages

"Fabry Disease therapeutic market is USD 1028 million in 2017 in seven major markets for the study period (2017-2028)."

Among EU5 countries, Germany had the highest market size with USD 94 million, while Spain had the lowest market size of Fabry Disease with USD 55 million in 2017. Therapeutic management primarily focuses on the control of blood pressure, lipids, and proteinuria. ACE inhibitors and/or blockers should be used in patients with proteinuria. Hypertension and hypercholesterolemia should be managed appropriately. Prophylaxis with anticoagulants is important in patients who have had ischemic attacks or stroke, and permanent cardiac pacing should be considered in high-risk patients. Furthermore, patients need to be encouraged to maintain a healthy lifestyle.
The effective management of Fabry disease requires a multidisciplinary approach. Comprehensive therapy includes intravenously administered enzyme replacement therapy (ERT) or Oral Chaperone Therapy, conventional medical treatment, and adjunct therapies, and may include lifestyle modifications and prophylactic medications. Fabry disease treatment primarily focuses upon replacing the missing or deficient enzyme (alpha-galactosidase A, or alpha-Gal A). All classically affected males (i.e., with very low or undetectable levels of alpha-Gal A) receive enzyme replacement therapy (ERT) as soon as the diagnosis is made, regardless of whether or not clinical manifestations are present. Female carriers and atypically affected males (i.e., with marginal levels of alpha-Gal A) receive ERT if clinical manifestations (e.g., renal, neurologic, cardiovascular) are present.
There are several companies which are working robustly on developing new therapies with novel mechanism of action to provide better Fabry Disease treatment options.

The key players are:
1. Sanofi-Genzyme
2. Amicus Therapeutics
3. Shire
4. Idorsia Pharmaceuticals
5. Protalix Biotherapeutics
And many others

Drugs covered
1. Fabrazyme
2. Galafold
3. Replagal
4. Lucerastat
5. Pegunigalsidase alfa
And many others

Table of contents

1. Report Introduction
2. Fabry Disease Market Overview at a Glance
3. Fabry Disease Disease Background and Overview
4. Fabry Disease Epidemiology and Patient Population
4.1. United States
4.2. United Kingdom
4.3. Spain
4.4. Italy
4.5. France
4.6. Germany
4.7. Japan
5. Fabry Disease Treatment Practices
6. Fabry Disease Marketed Drugs List
6.1. Marketed Drugs
6.1.1. Galafold: Amicus Therapeutics, Inc.
6.1.2. Replagal: Shire Plc.
6.1.3. Fabrazyme: Sanofi-Aventis
7. Emerging Therapies
7.1. Phase-III Drugs Analysis
7.2. Expert commentary for Key Emerging Drugs
7.3. Phase III and Filed Drugs
7.3.1. Pegunigalsidase alfa: Protalix Biotherapeutics
7.3.2. Lucerastat: Idorsia Pharmaceuticals
8. Market Outlook by Country
9. The United States: Market Outlook
9.1. United States Market Size
9.2. EU-5 Countries: Market Outlook
9.3. Germany
9.4. France
9.5. Italy
9.6. Spain
9.7. United Kingdom
10. Japan Market Outlook
10.1. Fabry Disease Total Market Size
10.2. Fabry Disease Market Size by Therapies
11. Market Drivers
12. Market Barriers
13. Appendix
14. Report Methodology
15. Disclaimer
16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight